Key points are not available for this paper at this time.
Glucocorticoids represent frequently recommended and often indispensable immunosuppressant and anti-inflammatory agents prescribed in various medical conditions. Despite their proven efficacy, glucocorticoids bear a wide variety of side effects among which steroid induced hyperglycaemia (SIHG) is among the most important ones. SIHG, potentially causes new-onset hyperglycaemia or exacerbation of glucose control in patients with previously known diabetes. Retrospective data showed that similar to general hyperglycaemia in diabetes, SIHG in the hospital and in outpatient settings detrimentally impacts patient outcomes, including mortality. However, recommendations for treatment targets and guidelines for in-hospital as well as outpatient therapeutic management are lacking, partially due to missing evidence from clinical studies. Still, SIHG caused by various types of glucocorticoids is a common challenge in daily routine and clinical guidance is needed. In this review, we aimed to summarize clinical evidence of SIHG in inpatient care impacting clinical outcome, establishment of diagnosis, diagnostic procedures and therapeutic recommendations.
Building similarity graph...
Analyzing shared references across papers
Loading...
Felix Aberer
University of Graz
Daniel A. Hochfellner
Medical University of Graz
Harald Sourij
University of Graz
Journal of Clinical Medicine
Medical University of Graz
Building similarity graph...
Analyzing shared references across papers
Loading...
Aberer et al. (Sun,) studied this question.
synapsesocial.com/papers/6a01ccb30cec8eebbd5cad8d — DOI: https://doi.org/10.3390/jcm10102154
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: